ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 1339 • ACR Convergence 2023

    Neutrophil Activation and Formation of Neutrophil Extracellular Traps Are Associated with Response to Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis

    Ting Wang1, Natalia V. Giltiay2, Christian Lood2 and Bobby Kwanghoon Han2, 1University of Washington, Seattle, WA, 2Division of Rheumatology, University of Washington, Seattle, WA

    Background/Purpose: Neutrophil activation and formation of neutrophil extracellular traps (NETs) have been implicated in the pathogenesis of rheumatoid arthritis (RA). Calprotectin, a neutrophil activation marker,…
  • Abstract Number: 1643 • ACR Convergence 2023

    Exploring the Serum Metabolome for Potential Diagnostic Markers of Psoriatic Arthritis

    Nikita Looby1, Max Kotlyar2, Chiara Pastrello2, Darshini Ganatra1, Vathany Kulasingam3, Igor Jurisica4 and Vinod Chandran5, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 2Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, 3Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, 4Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, 5Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory immune-mediated musculoskeletal skin disease that affects approximately 25% of psoriasis patients causing progressive disability. As a heterogeneous disease,…
  • Abstract Number: 1792 • ACR Convergence 2023

    Identifying Synovial Fluid Micro-RNA Signature That Distinguishes Psoriatic Arthritis from Osteoarthritis

    Darshini Ganatra1, Anas Samman1, David Nasri1, Sara Rahmati1, Omar Cruz Correa1, Rohan Machhar1, Rajiv Gandhi2, Mohit Kapoor3 and Vinod Chandran4, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Orthopaedics, Department of Surgery, University of Toronto, Toronto, ON, Canada, 3Schroeder Arthritis Institute, University Health Network and Department of Surgery, University of Toronto, Toronto, ON, Canada, 4Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Psoriatic Arthritis (PsA) is an inflammatory arthritis and shares several clinical features with Osteoarthritis (OA), the most common form of arthritis. This often leads…
  • Abstract Number: 2221 • ACR Convergence 2023

    Clinical and Molecular Patterns Associated with Persistence of Inflammation in Spondyloarthritis Patients: Unveiling Potential Biomarkers

    Lourdes Ladehesa Pineda1, Ivan Arias de la Rosa2, Laura Cuesta-López3, Clementina López Medina4, María Ángeles Puche Larrubia5, Miriam Ruiz-Ponce3, María del carmen Ábalos Aguilera3, Pedro Ortiz Buitrago3, Yasin Hanaee3, Carlos Perez-Sanchez6, Chary López-Pedrera3, Alejandro Escudero-Contreras7, Eduardo Collantes Estévez8 and Nuria Barbarroja9, 1Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, 2IMIBIC/Reina Sofia Hospital/University of Cordoba. Rheumatology service. Cordoba. Spain, Cordoba, Spain, 3IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 4Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, 5Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, 6IMIBIC, Córdoba, Spain, 7Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain, 8Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, 9University of Cordoba, Córdoba, Spain

    Background/Purpose: Chronic inflammation is closely associated with an increased risk of cardiovascular diseases (CVD) through the activation of the immune system and the release of…
  • Abstract Number: 2364 • ACR Convergence 2023

    Circulating CTHRC1 Levels Are Associated with Disease Severity and Predict Survival in Systemic Sclerosis

    Monica Yang1, Seoyeon Lee2, Lisa Hazelwood3, Dean Sheppard1, Francesco Boin4 and Paul Wolters1, 1University of California San Francisco, San Francisco, CA, 2Yale University School of Medicine, New Haven, CT, 3AbbVie, Inc., North Chicago, IL, 4Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose: Despite recent advances in systemic sclerosis (SSc), there remains a paucity of clinically actionable biomarkers to assess disease severity and predict progression. Collagen triple…
  • Abstract Number: 2572 • ACR Convergence 2023

    Autoantibody Profile of Autoimmune Driven Interstitial Lung Disease as Compared to Idiopathic Pulmonary Fibrosis and Association of Autoantibodies with Survival

    Elena Joerns1, Chad Newton2, Stanislav Kolenikov3, Jeffrey Sparks4 and David Karp5, 1University of Texas Southwestern Medical Center, Dallas, TX, 2UT Southwestern, Dallas, TX, 3NORC at the University of Chicago, Columbia, MO, 4Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 5UT Southwestern Medical Center, Dallas, TX

    Background/Purpose: The term interstitial pneumonia with autoimmune features (IPAF) describes patients with interstitial lung disease (ILD) and features of autoimmunity, that do not fulfill classification…
  • Abstract Number: 0090 • ACR Convergence 2023

    Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis

    Addison Pacheco1, Michael Tang1, Sinead Maguire2, Melissa Lim1, Fataneh Tavasolian3, Zoya Qaiyum4 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2Toronto Western Hospital, Toronto, ON, Canada, 3Krembil Research Institute, University Health Network, Toronto, ON, Canada, 4Krembil Research Institute, Toronto, ON, Canada

    Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory disease that predominantly affects the spine and the sacroiliac joints. Dysregulation of Type 3 immunity has been implicated…
  • Abstract Number: 0503 • ACR Convergence 2023

    Spinal Inflammation a Dominant Pathology in Psoriatic Arthritis: Characterization and Quantification by In-Vivo 18F-FDG Total-Body PET/CT Imaging

    Siba Raychaudhuri1, Yasser Abdelhafez2, Dario Mazza2, Smriti K Raychaudhuri3 and Abhijit Chaudhari4, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 2University of California Davis, Sacramento, CA, 3VA Sacramento Medical Center, Mather, CA, 4UC Davis School of Medicine, Sacramento, CA

    Background/Purpose: Right and Moll recognized the presence of spinal inflammation/axial disease in psoriatic arthritis (PsA) in their seminal work in 1973. The prevalence of axial…
  • Abstract Number: 0598 • ACR Convergence 2023

    Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study

    Richard Furie1, Victoria Werth2, Eric Milliman3, Kyle Ferber3, Fergal Casey3, Roland Brown3, Denitza Raitcheva3, Jad Zoghbi3, Danielle Graham3, George Kong3, Youmna Lahoud3, Nathalie Franchimont4 and Catherine Barbey5, 1Northwell Health, Manhasset, NY, 2University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, PA, 3Biogen, Cambridge, MA, 4Former employee of Biogen, Cambridge, MA, 5Biogen, Baar, Switzerland

    Background/Purpose: Litifilimab is a humanized IgG1 mAb targeting BDCA2, a receptor expressed on plasmacytoid dendritic cells (pDCs), that negatively regulates the production of Type I…
  • Abstract Number: 0848 • ACR Convergence 2023

    Performance of Serum MRP8/14, sCD14, IL-6 and Neutrophil CD64 in Isolation and in Combination for Differentiating Flare from Bacterial Infection in Febrile SLE Patients

    Kishan Majithiya1, Komal Singh1, Pankti Mehta2, Chengappa Kavadichanda3, seema Sharma1, Able Lawrence1 and Amita Aggarwal1, 1Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, 2King George's Medical University, Mumbai, India, 3Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India

    Background/Purpose: Disease flare and infections are the major causes of fever in a patient with SLE. It is vital to differentiate between these two as…
  • Abstract Number: 1137 • ACR Convergence 2023

    Association Between Nailfold Videocapillaroscopy Findings and sKL-6 Levels in Patients with Idiopathic Inflammatory Myopathies–Related Interstitial Lung Disease

    Cristiana Sieiro Santos1, Jose Luis Tandaipan2, Diego Castillo2, Laura Martínez Martínez2, Helena Codes2, Luis Sainz-Comas2, Berta Paula Magallares-Lopez3, Patricia Moya2, Anais Mariscal2, Hye Sang Park2, Ana Milena Millán Arciniegas2, César Díaz-Torné2, Ana Laíz Alonso2, Sandra Ros2, Susana Fernández2, Hector Corominas4, Elvira Díez Álvarez5 and Iván Castellvi2, 1Complejo Asistencial Universitario de León, León, Spain, 2Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 3Department of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, 4Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain, 5CAULE, León, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a frequent pulmonary manifestation in idiopathic inflammatory myopathies (IIM) (IIM-ILD) and considerably influences morbidity and mortality. Krebs von den…
  • Abstract Number: 1367 • ACR Convergence 2023

    Novel Autoantibodies Might Circumvent the Need for Labial Biopsy in a Subset of Seronegative Sjögren’s Disease Patients

    Maxwell Parker1, Zihao Zheng2, Michael Lasarev3, Roxana Alexandridis3, Michael Newton3, Miriam Shelef3 and Sara McCoy4, 1University of Wisconsin-Madison, Madison, WI, 2Google, Sunnyvale, CA, 3University of Wisconsin, Madison, WI, 4University of Wisconsin School of Medicine and Public Health, Middleton, WI

    Background/Purpose: Sjögren's disease (SjD) is typically diagnosed by the presence of an anti-SSA antibody or focal lymphocytic sialadenitis in salivary gland tissue. Among SjD patients…
  • Abstract Number: 1689 • ACR Convergence 2023

    Deep Cellular Immune Profiling in Psoriatic Arthritis Correlates with Imaging Phenotypes and Response to Targeted Advanced Therapy

    Lihi Eder1, Xianwei Li2, Sydney Thib3, Darshini Ganatra4, Liqun Diao2 and Vinod Chandran5, 1Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 2Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 3Women’s College Research Institute, Toronto, ON, Canada, 4Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 5Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: To characterize the relationships between peripheral blood immune cell profiles in patients with psoriatic arthritis (PsA) and (1) baseline clinical and imaging disease features;…
  • Abstract Number: 1794 • ACR Convergence 2023

    The Role of the Deubiquitinase ZRANB1/TRABID in Inflammation and Bone Formation in Spondyloarthritis

    Archita Srinath1, Daniele Mauro2, Francesco Ciccia3 and Nigil Haroon4, 1University of Toronto, Toronto, ON, Canada, 2University of Campania, Naples, Italy, 3University of Campania - Luigi Vanvitelli, Naples, Italy, 4University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada

    Background/Purpose: Inflammation and new bone formation are important disease mediators in ankylosing spondylitis (AS). Recent studies in mice show that the deubiquitinase molecule TRABID epigenetically…
  • Abstract Number: 2273 • ACR Convergence 2023

    Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine

    Vasileios Kyttaris1, Tyler O'Malley2, Giorgio Casaburi2, Sudha Kumar2 and Andrew Concoff3, 1BIDMC, Boston, MA, 2Exagen, Vista, CA, 3Exagen, Los Angeles, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease with diverse clinical manifestations and variable treatment response. Conventional biomarkers of SLE activityprovide modest correlation…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology